Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C16H23NO |
Molecular Weight | 245.3599 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC3=C(C=C(O)C=C3)[C@@](C)(CCCCC1)[C@H]2N
InChI
InChIKey=VTMVHDZWSFQSQP-VBNZEHGJSA-N
InChI=1S/C16H23NO/c1-16-8-4-2-3-5-12(15(16)17)9-11-6-7-13(18)10-14(11)16/h6-7,10,12,15,18H,2-5,8-9,17H2,1H3/t12-,15-,16+/m0/s1
Molecular Formula | C16H23NO |
Molecular Weight | 245.3599 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Dezocine was discovered and patented by American Home Products Corp. in 1978. Dezocine is a partial opiate drug and was used for pain management under brand name Dalgan. But then usage of this drug was discontinued in US. Dezocine acts as a partial μ-receptor agonist, a κ-receptor antagonist, and a norepinephrine and serotonin reuptake inhibitor (via norepinephrine transporter and serotonin transporter). Dezocine shares the CNS depressant and respiratory depressant effects of opioid analgesics. Dezocine has not been shown to produce clinically significant cardiovascular adverse effects.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL233 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24263237 |
3.7 nM [Ki] | ||
Target ID: CHEMBL237 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16433932 |
24.5 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sources: https://www.drugs.com/mmx/dalgan.html |
Primary | DALGAN Approved UseUnknown Launch Date1989 |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
117.1 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3709625 |
20 mg single, intravenous dose: 20 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
DEZOCINE serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
23.7 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3709625 |
5 mg single, intravenous dose: 5 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
DEZOCINE serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
49.1 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3709625 |
10 mg single, intravenous dose: 10 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
DEZOCINE serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3709625 |
20 mg single, intravenous dose: 20 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
DEZOCINE serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
2.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3709625 |
5 mg single, intravenous dose: 5 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
DEZOCINE serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
2.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3709625 |
10 mg single, intravenous dose: 10 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
DEZOCINE serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
10 mg single, intramuscular Highest studied dose Dose: 10 mg Route: intramuscular Route: single Dose: 10 mg Sources: |
healthy, 18-52 years n = 24 Health Status: healthy Age Group: 18-52 years Sex: M Population Size: 24 Sources: |
|
10 mg single, subcutaneous Highest studied dose Dose: 10 mg Route: subcutaneous Route: single Dose: 10 mg Sources: |
healthy, 18-52 years n = 24 Health Status: healthy Age Group: 18-52 years Sex: M Population Size: 24 Sources: |
|
20 mg single, intravenous Highest studied dose Dose: 20 mg Route: intravenous Route: single Dose: 20 mg Sources: |
healthy, 18-52 years n = 12 Health Status: healthy Age Group: 18-52 years Sex: M Population Size: 12 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Cocaine-like discriminative stimulus effects and [3H]dopamine uptake inhibition produced by selected partial opioid agonists. | 2001 Jul |
|
Three-choice discrimination in pigeons is based on relative efficacy differences among opioids. | 2001 Jun |
|
Activation profiles of opioid ligands in HEK cells expressing delta opioid receptors. | 2002 Nov 18 |
|
Activity of opioid ligands in cells expressing cloned mu opioid receptors. | 2003 Jan 4 |
|
The effect of preoperative ketorolac on WBC response and pain in laparoscopic surgery for endometriosis. | 2005 Dec 31 |
|
Sevoflurane requirement during elective ankle day surgery: the effects of etirocoxib premedication, a prospective randomised study. | 2008 Sep 11 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/mmx/dalgan.html
Intravenous: 5-mg dose, 10-mg dose and 20-mg dose
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22931048
Curator's Comment: Aliquots of sperm were incubated with various concentrations of opioid analgesics in vitro. Computer-assisted sperm analysis was used to assess sperm motility at 15 minutes, 2 hours, and 4 hours after drug addition to the medium. Dezocine showed marked reduction of motility after incubation with sperm for 15 minutes. Based on the data reported herein, it has been found, that dezocine exert a sperm-immobilizing effect.
Unknown
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 16:45:38 GMT 2023
by
admin
on
Sat Dec 16 16:45:38 GMT 2023
|
Record UNII |
VHX8K5SV4X
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C67413
Created by
admin on Sat Dec 16 16:45:38 GMT 2023 , Edited by admin on Sat Dec 16 16:45:38 GMT 2023
|
||
|
WHO-ATC |
N02AX03
Created by
admin on Sat Dec 16 16:45:38 GMT 2023 , Edited by admin on Sat Dec 16 16:45:38 GMT 2023
|
||
|
NCI_THESAURUS |
C1506
Created by
admin on Sat Dec 16 16:45:38 GMT 2023 , Edited by admin on Sat Dec 16 16:45:38 GMT 2023
|
||
|
WHO-VATC |
QN02AX03
Created by
admin on Sat Dec 16 16:45:38 GMT 2023 , Edited by admin on Sat Dec 16 16:45:38 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB01209
Created by
admin on Sat Dec 16 16:45:38 GMT 2023 , Edited by admin on Sat Dec 16 16:45:38 GMT 2023
|
PRIMARY | |||
|
4474
Created by
admin on Sat Dec 16 16:45:38 GMT 2023 , Edited by admin on Sat Dec 16 16:45:38 GMT 2023
|
PRIMARY | |||
|
100000082882
Created by
admin on Sat Dec 16 16:45:38 GMT 2023 , Edited by admin on Sat Dec 16 16:45:38 GMT 2023
|
PRIMARY | |||
|
VHX8K5SV4X
Created by
admin on Sat Dec 16 16:45:38 GMT 2023 , Edited by admin on Sat Dec 16 16:45:38 GMT 2023
|
PRIMARY | |||
|
DTXSID2022911
Created by
admin on Sat Dec 16 16:45:38 GMT 2023 , Edited by admin on Sat Dec 16 16:45:38 GMT 2023
|
PRIMARY | |||
|
847
Created by
admin on Sat Dec 16 16:45:38 GMT 2023 , Edited by admin on Sat Dec 16 16:45:38 GMT 2023
|
PRIMARY | |||
|
SUB07059MIG
Created by
admin on Sat Dec 16 16:45:38 GMT 2023 , Edited by admin on Sat Dec 16 16:45:38 GMT 2023
|
PRIMARY | |||
|
3033053
Created by
admin on Sat Dec 16 16:45:38 GMT 2023 , Edited by admin on Sat Dec 16 16:45:38 GMT 2023
|
PRIMARY | |||
|
DEZOCINE
Created by
admin on Sat Dec 16 16:45:38 GMT 2023 , Edited by admin on Sat Dec 16 16:45:38 GMT 2023
|
PRIMARY | |||
|
C010827
Created by
admin on Sat Dec 16 16:45:38 GMT 2023 , Edited by admin on Sat Dec 16 16:45:38 GMT 2023
|
PRIMARY | |||
|
m4229
Created by
admin on Sat Dec 16 16:45:38 GMT 2023 , Edited by admin on Sat Dec 16 16:45:38 GMT 2023
|
PRIMARY | Merck Index | ||
|
CHEMBL1685
Created by
admin on Sat Dec 16 16:45:38 GMT 2023 , Edited by admin on Sat Dec 16 16:45:38 GMT 2023
|
PRIMARY | |||
|
3906
Created by
admin on Sat Dec 16 16:45:38 GMT 2023 , Edited by admin on Sat Dec 16 16:45:38 GMT 2023
|
PRIMARY | |||
|
22713
Created by
admin on Sat Dec 16 16:45:38 GMT 2023 , Edited by admin on Sat Dec 16 16:45:38 GMT 2023
|
PRIMARY | RxNorm | ||
|
53648-55-8
Created by
admin on Sat Dec 16 16:45:38 GMT 2023 , Edited by admin on Sat Dec 16 16:45:38 GMT 2023
|
PRIMARY | |||
|
C65374
Created by
admin on Sat Dec 16 16:45:38 GMT 2023 , Edited by admin on Sat Dec 16 16:45:38 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |